- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
-
April 12, 2021Robins Kaplan Executives Recognized by Twin Cities Business
-
April 1, 2021Robert Bennett Named a Midwest Trailblazer
-
March 31, 2021Robins Kaplan Attorneys Earn 2021 Readers' Choice Awards from JD Supra
-
April 13, 20, and 27, 2021Conversations on Cross-Border IP Protection and Enforcement
-
April 28, 2021Creating the Audit Clause for Today’s Compliance Review
-
April 29, 2021International Intellectual Property: Challenges of Cross-Border Litigation
-
April 2, 2021Prepare For Minn. Privacy Law To Catch Up To Calif., Wash.
-
Spring 2021Fiduciary or Foe? Revisiting Meinhard v. Salmon
-
Spring 2021Shareholder Risks in Mergers and Acquisitions
-
April 13, 2021Financial Daily Dose 4.13.2021 | Top Story: Ant Group Agrees to Sweeping Overhaul to Appease Chinese Regulators
-
April 12, 2021Financial Daily Dose 4.12.2021 | Top Story: Chinese Regulators Hit Alibaba With $2.8B Antitrust Fine
-
April 9, 2021Financial Daily Dose 4.9.2021 | Top Story: CV Amazon Leading in Early Alabama Warehouse Union-Vote Tally
Power Morcellators
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
On April 17, 2014 the FDA cautioned that power morcellators, a type of surgical tool used in laparoscopic and robotic hysterectomies and fibroid removal procedures, may promote the spread of unsuspected uterine cancer. In response, Johnson & Johnson, the largest manufacturer of the devices, suspended worldwide sales of its laparoscopic power morcellators.
Laparoscopic power morcellation is one of several available treatments for fibroids. It is a procedure that uses a medical device to divide the uterine tissue into smaller pieces or fragments so it can be removed through a small incision in the abdomen. The FDA has determined that approximately 1 in 350 women who are undergoing hysterectomy or myomectomy for fibroids have an unsuspected type of uterine cancer called uterine sarcoma. If laparoscopic power morcellation is performed in these women, there is a risk that the procedure will spread the cancerous tissue within the abdomen and pelvis, significantly worsening the patient’s likelihood of long-term survival. The FDA is now urging doctors to avoid using power morcellators during uterine fibroid treatments.
Robins Kaplan LLP is interested in speaking with individuals who have undergone a power morcellation hysterectomy or fibroid removal procedure and were then diagnosed with uterine cancer, endometrial cancer, leiomyosarcoma, uterine sarcoma, or another cancer that has spread throughout the body.
Robins Kaplan LLP is experienced with medical device suits and is dedicated to giving our clients a voice against large companies. We welcome calls from referring attorneys or potential clients. Contact us at 1.612.349.8500 or 1.800.553.9910
[2] Wall Street Journal, Johnson & Johnson Suspends Sale of Device Used in Fibroid Surgery, April 29, 2014, http://online.wsj.com/news/articles/SB10001424052702304893404579531961812995326
[3] http://www.fda.gov/newsEvents/Newsroom/PressAnnouncements/ucm393689.htm
[4] Id.
[5] Id.
[6] Id.
[6] Id.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.